Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tonsillar Immune Response to SLIT and LAIV
NCT01924208Phase 3Unknown
- Sponsor
- Turku University Hospital
- Start
- Oct 2013
- Primary completion
- Sep 2016
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of phleum pratense extract and live attenuated influenza vaccine in allergic rhinitis (AR) and influenza (4 arms), sponsored by Turku University Hospital. Primary endpoint: Expressions of interferon and T cell and closely related cytokines and transcription factors in tonsils up to 3 years. Status: unknown.
02
Drugs
phleum pratense extractlive attenuated influenza vaccine
03
Conditions
allergic rhinitis (AR)influenza
Beyond the preview
Go deeper on NCT01924208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01924208.